GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfront

The year of an­ti­body-drug con­ju­gates isn’t done yet, as GSK is adding an­oth­er li­cens­ing part­ner­ship with Han­soh Phar­ma for an­oth­er ADC with an up­front pay­ment of $185 mil­lion. There is al­so up to $1.525 bil­lion in mile­stone pay­ments in store for Han­soh, ac­cord­ing to a Hong Kong Stock Ex­change fil­ing.

In Oc­to­ber, the com­pa­nies an­nounced that GSK will li­cense an ADC from Han­soh, named HS-20089, with an $85 mil­lion up­front and a fur­ther $1.48 bil­lion in mile­stone pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.